Compare Gilead Sciences, Inc. (GILD) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wahed FTSE USA Shariah ETF — how do they compare? Gilead Sciences, Inc. trades at $151.02 (market cap $182.40B), while Wahed FTSE USA Shariah ETF trades at $75.93 (market cap $1.00B). The key difference: Gilead Sciences, Inc. is far larger — about 182.4× Wahed FTSE USA Shariah ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Wahed FTSE USA Shariah ETF for 65 Days on average.
| GILD | HLAL | |
|---|---|---|
Market Cap | $182.40B | $1.00B |
Volume | 4,469,821 | 51,137 |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $76.54 |
52-Week Low | $116.74 | $57.46 |
Typical Hold Time | 111 Days | 65 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
